Arbutus Biopharma (ABUS) Other Non Operating Income (2013 - 2026)
Arbutus Biopharma (ABUS) posted quarterly Other Non Operating Income of -$11000.0 for Q1 2026, down 375.0% year-on-year from $4000.0 in Q1 2025, and down 1200.0% on a QoQ basis from $1000.0 in Q4 2025.
Arbutus Biopharma (ABUS) Other Non Operating Income (2013 - 2026) Analysis & Trends
Arbutus Biopharma (ABUS) has reported Other Non Operating Income for 14 consecutive years, with -$11000.0 the latest figure, recorded in Q1 2026.
- Quarterly Other Non Operating Income fell 375.0% year-over-year to -$11000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1000.0 (up 96.88% YoY) and the FY2025 annual result came in at $14000.0, up 128.57% from the prior year.
- Other Non Operating Income eased to -$11000.0 in Q1 2026 per ABUS's latest filing, from $1000.0 in the prior quarter.
- Over the last five years, Other Non Operating Income for ABUS reached as high as $21000.0 in Q2 2025 and fell as low as -$33000.0 in Q4 2024.
- A 5-year average of -$2687.5 and a median of $1000.0 in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2023 — Other Non Operating Income jumped 450.0% — and 2024, when it slumped 900.0%.
- Year by year, Other Non Operating Income stood at -$4000.0 in 2022, then soared by 450.0% to $14000.0 in 2023, then slumped by 335.71% to -$33000.0 in 2024, then jumped by 103.03% to $1000.0 in 2025, then sank by 1200.0% to -$11000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$11000.0, $1000.0, and -$12000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Arbutus Biopharma | 880.36 Mn | 785.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | -12,000.00 |
| Jun 30, 2025 | 21,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | -33,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Mar 31, 2024 | -13,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Sep 30, 2023 | 6,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Dec 31, 2022 | -4,000.00 |
| Sep 30, 2022 | -21,000.00 |
| Jun 30, 2022 | 3,000.00 |
| Dec 31, 2021 | 5,000.00 |
| Sep 30, 2021 | -15,000.00 |
| Jun 30, 2021 | -13,000.00 |
| Mar 31, 2021 | 28,000.00 |